Literature DB >> 8410287

Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.

O S Hoekstra1, G J Ossenkoppele, R Golding, A van Lingen, G W Visser, G J Teule, P C Huijgens.   

Abstract

Clinical oncology needs flexible techniques for routine monitoring of treatment response. We therefore compared planar 18F-fluorodeoxyglucose (FDG) with a conventional gamma-camera and a special collimator to 67Ga scintigraphy in 26 patients with malignant lymphoma during chemotherapy. The scintigraphic appearance of involved sites was essentially the same with both tracers: in patients eventually achieving complete remission, tracer distribution had normalized after two courses; high uptake reflected treatment failure; faint uptake was associated with variable outcome. For (re)staging, 67Ga may be preferable (higher contrast). To document the initial response, we performed FDG scintigraphy during the first course (n = 11). Effective treatment sharply reduced metabolic tumor activity within days and prior to volume response, whereas abnormal uptake persisted in treatment failure. Planar FDG scintigraphy may be a tool to assess the potentially prognostic initial response rate, preventing over-treatment and allowing a timely switch to more aggressive therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410287

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

1.  [The value of gallium scintigraphy after the therapy of Hodgkin's disease].

Authors:  S Staar
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

Review 2.  Fluorine 18-labeled fluorodeoxyglucose myocardial scintigraphy with Anger gamma cameras for assessing myocardial viability.

Authors:  M J Kelly; V Kalff
Journal:  J Nucl Cardiol       Date:  1995 Jul-Aug       Impact factor: 5.952

Review 3.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

4.  An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.

Authors:  Heather Keen; Bernd Pichler; Damaris Kukuk; Olivier Duchamp; Olivier Raguin; Aoife Shannon; Nichola Whalley; Vivien Jacobs; Juliana Bales; Neill Gingles; Sally-Ann Ricketts; Stephen R Wedge
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

5.  [Importance of PET/CT in lymphoma diagnostics].

Authors:  A Afshar-Oromieh; C Kratochwil; U Haberkorn; F L Giesel
Journal:  Radiologe       Date:  2012-04       Impact factor: 0.635

6.  Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography.

Authors:  O S Hoekstra; A van Lingen; G J Ossenkoppele; R Golding; G J Teule
Journal:  Eur J Nucl Med       Date:  1993-12

7.  Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT.

Authors:  Anat Ilivitzki; Lea Radan; Miriam Ben-Arush; Ora Israel; Ayelet Ben-Barak
Journal:  Pediatr Radiol       Date:  2012-11-14

8.  Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management.

Authors:  C B Wilson; H E Young; R J Ott; M A Flower; B F Cronin; B E Pratt; V R McCready; A Horwich
Journal:  Eur J Nucl Med       Date:  1995-06

Review 9.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

10.  Relationship Between Dual Time Point FDG PET/CT and Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study.

Authors:  Do Hyoung Lim; Jai Hyuen Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.